Cancer Centre – Research

Cancer trials test new, improved, and better ways to prevent, diagnose and treat cancer. For most of our cancer trials, patients either receive standard treatments for cancer or the new treatment being investigated.

Study: MOUNTAINEER-03

• Purpose: This trial is for people with advanced bowel cancer that has spread and has a HER2 marker, to see if a combination of targeted drugs (tucatinib and trastuzumab) with chemotherapy works better than standard treatment.
• Status: Open to referrals
• Led by: Dr. Darren Cowzer

Study: NATALEE

• Purpose: For people with: This trial is for people with early-stage breast cancer that is hormone-sensitive and HER2-negative, to see if adding a new medicine (ribociclib) to standard hormone therapy can reduce the risk of the cancer returning after initial treatment.
• Status: Closed, patients in follow up
• Led by: Prof. Catherine Kelly & Prof. John McCaffrey

Study: CAMBRIA-2

• Purpose: This trial is for people with early-stage breast cancer that is hormone receptor-positive and HER2-negative, to see if a new hormone-based treatment (camizestrant) after initial therapy can help prevent the cancer from coming back.
• Status: Closed to new patients

Study: TREAT ctDNA

• Purpose: This trial is for people with hormone receptor positive, HER2 negative breast cancer who have no visible disease but have signs of cancer DNA in their blood, to see if a new hormone treatment (elacestrant) can help prevent the cancer from coming back.
• Status: Open to referrals
• Led by: Prof. Catherine Kelly

Study: KRYSTAL-4

• Purpose: This trial is for people with a specific type of lung cancer that has not yet been treated and has a KRAS G12C mutation, to see if adding a new targeted drug (adagrasib) to standard immunotherapy and chemotherapy improves outcomes.
• Status: Open to referrals
• Led by: Dr. Jane Sui

Study: RASolve 301

• Purpose: This trial is for people with lung cancer that has already been treated and cannot be removed or has spread, to see if a new targeted drug (RMC 6236) works better than standard chemotherapy.
• Status: Open to referrals
• Led by: Dr. Jane Sui

Study: ARTEMIDE Lung04

• Purpose: This trial is for people with advanced bowel cancer that has spread and has a HER2 marker, to see if a combination of targeted drugs (tucatinib and trastuzumab) with chemotherapy works better than standard treatment.
• Status: Open to referrals
• Led by: Dr. Jane Sui

Study: SIMPLIFY-SABR-COMET

• Purpose: This trial is for people with a small number of areas where their cancer has spread, to see if giving radiotherapy in one session works as well as several sessions for treating all sites of disease.
• Status: Open to referrals
• Led by: Prof. Daniel Cagney

Study: Isa-RVD Study

• Purpose: This trial is for people who have just been diagnosed with multiple myeloma, to see how well a combination of four drugs works as their first treatment.
• Status: Closed to new patients
• Led by: Prof. Peter O'Gorman

Study: ENZAMET ICORG 14-06

• Purpose: This trial is for men with prostate cancer that has already spread to other parts of the body who are starting hormone therapy for the first time, to test whether adding a new drug (enzalutamide) improves outcomes.
• Status: Closed
• Led by: Prof. John McCaffrey

Study: DASL-HICAP

• Purpose: This trial is for men with very high-risk prostate cancer that has not yet spread far, to see if adding a new drug (darolutamide) to standard treatment improves outcomes.
• Status: Closed
• Led by: Prof. John McCaffrey

Study: PEACE6-Vulnerable

• Purpose: This trial is for men whose prostate cancer has already spread when first diagnosed and who may be more physically vulnerable, to see if adding darolutamide to standard hormone therapy is helpful and safe.
• Status: Open to referrals

Study: PEACE 8

• Purpose: This trial is for men with prostate cancer that is no longer responding to hormone therapy and has spread to a small number of areas, to see if adding a new hormone treatment (darolutamide) to precise targeted radiotherapy improves outcomes.
• Status: Opening soon
• Led by: Prof. Daniel Cagney

Study: DE-ESCALATE

• Purpose: This trial is for men with prostate cancer that is no longer responding to hormone therapy, to see if taking hormone treatment breaks (instead of continuous treatment) works as well and improves quality of life when combined with newer treatments.
• Status: Opening soon
• Led by: Dr. Waseem Darwish & Prof. John McCaffrey